Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV vaccine there is expected to hurt 2025 revenue, but it still posted a strong ...

Merck & Co (NYSE:MRK), the New Jersey-based pharmaceutical giant, has announced a halt in shipments of its Gardasil vaccine to China, a move that has negatively impacted the company's sales forecast.

Merck said it will pause shipments of Gardasil to China through at least mid-year, as continued weak demand for the HPV ...